Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Leon – page 4

100 clinical trials in Leon, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Leon at a glance
100
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

100 trials in Leon

Open in trial search

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Not yet recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Not yet recruiting

Evaluation of Datopotamab Deruxtecan in Patients with Non-Squamous Non-Small Cell Lung Cancer and Active Brain Metastases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Medica Scientia Innovation Research S.L.

Hepatitis alcoholic

Not yet recruiting

Study on the Effectiveness of N-Acetylcysteine and Methylprednisolone for Patients with Severe Acute Alcoholic Hepatitis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Bioaraba

Endometrial cancer

Not yet recruiting

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Asso De Recherche Cancers Gynecologiques

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Leon

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials targeting various types of cancer, including leukemia, lung cancer, and multiple myeloma. Studies focus on innovative therapeutic approaches combining immunotherapy with conventional treatments.

  • BCR-ABL1+ Chronic Myeloid Leukemia treatment studies
  • Advanced non-small cell lung cancer therapies
  • Multiple myeloma treatment innovations

Research includes evaluation of targeted therapies and novel drug combinations to improve patient outcomes.

02 Cardiovascular Studies

Comprehensive research investigating treatments for various heart conditions, with emphasis on coronary artery disease and prevention of cardiovascular events.

  • Antiplatelet therapy optimization
  • Spontaneous coronary artery dissection treatment
  • Major adverse cardiovascular event prevention

Studies aim to improve treatment strategies and reduce cardiovascular complications.

03 Metabolic and Emergency Medicine

Clinical research addressing urgent medical conditions and metabolic disorders, including septic shock and obesity management.

  • Weight management treatments
  • Septic shock interventions
  • Acute alcoholic hepatitis treatments

Focus on developing effective therapeutic approaches for critical conditions and metabolic disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.